BridgeBio Pharma (BBIO)

Executive Summary

BridgeBio Pharma is a clinical-stage biotechnology company developing transformative small-molecule medicines for genetic diseases and cancers. With a $13.43B market cap, the company employs a hub-and-spoke model, where autonomous teams focus on specific indications while leveraging centralized clinical, regulatory, and commercial capabilities. BridgeBio's lead asset, acoramidis (AG10), is a near-commercial stage therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), having demonstrated positive Phase 3 results in the ATTRibute-CM trial. Additionally, infigratinib is in Phase 3 for achondroplasia and other FGFR3-driven conditions, and BBP-631 is advancing for congenital adrenal hyperplasia. The company's diversified pipeline targets significant unmet medical needs in rare diseases. Upcoming milestones are expected to drive value. The primary catalyst is the submission of a New Drug Application (NDA) for acoramidis in ATTR-CM, which could occur in mid-2026, with a regulatory decision in early 2027. Additionally, Phase 3 topline data for infigratinib in achondroplasia is anticipated in the second half of 2026. A potential Phase 3 start for BBP-631 in CAH may also materialize. With a strong cash position and multiple late-stage programs, BridgeBio is well-positioned for potential approvals and commercial launches. Based on the pipeline maturity and recent positive data, the conviction score is 75.

Upcoming Catalysts (preview)

• Q2 2026NDA Submission for Acoramidis in ATTR-CM90% success
• Q3 2026Phase 3 Topline Data for Infigratinib in Achondroplasia70% success
• Q4 2026Phase 3 Initiation for BBP-631 in Congenital Adrenal Hyperplasia60% success